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CHAPTER I 
 
INTRODUCTION 
 
Cognitive dysfunction is fundamental to schizophrenia (Kraepelin & Robertson, 1971; 
Blueler, 1905) and readily demonstrated on a variety of neuropsychological instruments (Kolb & 
Whishaw, 1983).  Patients with schizophrenia typically perform one to two standard deviations 
below normal on a variety of measures; especially those that assess executive functions, verbal 
skills, processing speed, and attention (Hoff, Riordan, O'Donnell, Morris, & DeLisi, 1992; 
Saykin et al., 1994; Bilder et al., 2000; Fuller et al., 2002; Heinrichs & Zakzanis, 1998).  
Cognitive impairment in schizophrenia relates directly to socio-vocational functioning (Green, 
Kern, Braff, & Mintz, 2000; Green, 1996), and has been reported to exert a greater influence on 
functional outcome than the presence or severity of the positive or negative symptoms of 
schizophrenia (Velligan, Bow-Thomas, Mahurin, Miller, & Halgunseth, 2000).  A recent review 
and meta-analysis delineated the direct associations between neuropsychological functions and 
dimensions of outcome (Green et al., 2000).  Executive skill (i.e. WCST), secondary verbal 
memory, and verbal fluency were associated with community/daily living skills.  Secondary 
verbal memory and vigilance were related to social problem solving/instrumental skills.  
Immediate and secondary verbal memory were associated with psychosocial skill acquisition.  
An improvement in cognitive skill may thus have important consequences for rehabilitation, and 
the elucidation of particular associations between cognitive impairments and psychosocial 
limitations may provide a framework for the prediction of functional changes resulting from 
treatment-specific changes in cognitive status. 
With few exceptions, deficits on neuropsychological tests do not respond to treatment 
with first generation antipsychotics (FGAs).  Subtle and equivocal benefits from FGAs have 
been demonstrated on measures of attention (e.g. CPT, Digit Span), but no consistent changes 
have been reported on measures of general intellect, verbal skills, visual skills, executive skills, 
immediate recall or delayed recall (Spohn, Lacoursiere, Thompson, & Coyne, 1977; Spohn & 
Strauss, 1989; Blyler & Gold, 2000).  In fact, there is speculation that FGAs may have 
deleterious effects on specific cognitive skills, such as fine motor skill and procedural learning, 
deficits that presumably result from pharmacological blockade of D2 receptors at the dorsal 
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striatum  (Blyler & Gold, 2000; Purdon, Woodward, Mintz, & Labelle, 2002; Purdon, 
Woodward, Lindborg, & Stip, 2003; Stevens et al., 2002; Bedard, Scherer, Delorimier, Stip, & 
Lalonde, 1996; Bedard et al., 2000; Saint-Cyr, Taylor, & Lang, 1988; Farde et al., 1992; Kapur, 
Zipursky, & Remington, 1999).  Thus in some cognitive domains, traditional antipsychotics may 
not only fail to improve cognitive performance, but may actually lead to greater impairments 
(Carpenter & Gold, 2002).   
A body of evidence has begun to accumulate that suggests potential cognitive benefits 
from SGAs (e.g. Galletly, Clark, McFarlane, & Weber, 1999; Buchanan, Holstein, & Breier, 
1994; Bilder et al., 2002; Purdon, Malla, Labelle, & Lit, 2001).  The apparent cognitive 
enhancements may relate to the novel pharmacological properties of SGAs, such as a lower 
affinity for dorsal striatal D2 receptors and greater seretonergic activity relative to FGAs (Kapur 
et al., 1999; Kapur & Seeman, 2001; Kapur & Remington, 2001). While the former attribute 
likely underlies the reduced propensity of SGAs to induce EPS and procedural learning 
impairment, the latter might explain the cognitive advantages of SGAs over FGAs (Meltzer, 
1999; Chaudhry, Soni, Hellewell, & Deakin, 2002).  Pharmacological differences within the 
SGA class may also suggest dissociable effects on cognition.  For example, cholinergic 
inhibition adversely affects cognitive skills, particularly attention and memory (Bartus & 
Johnson, 1976; Frith, 1984; Spohn et al., 1989), and SGAs demonstrate variability in their degree 
of anticholinergic action.  Both olanzapine and clozapine have significant anticholiergic activity 
and, therefore, may not improve aspects of attention and memory to the same degree as 
risperidone and quetiapine.  This may be particular relevant to clozapine since it is typically 
prescribed at much higher doses despite having equivalent muscarinic receptor affinity as 
olanzapine (Lavalaye, Booij, Linszen, Reneman, & van Royen, 2001; Richelson & Souder, 2000; 
McGurk & Powchick, 2000).  Similarly, within the SGA class, risperidone has a relatively high 
affinity and long dissociation latency period for D2 receptors (Lavalaye et al., 1999; Seeman, 
2002), suggesting that patients receiving risperidone may be more likely to display adverse 
effects associated with dopamine antagonism in the striatum including greater EPS symptoms 
and reduced procedural learning.  A recent meta-analysis of EPS prevalence in clinical trials and 
preliminary evidence of reduced procedural learning with risperidone, relative to clozapine and 
olanzapine, provide support for this prediction (Leucht, Pitschel-Walz, Abraham, & Kissling, 
1999; Bedard et al., 2000; Purdon et al., 2003).  If EPS or procedural learning effects influence 
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performance on other cognitive domains, risperidone may produce a unique profile of 
neuropsychological benefits relative to other SGAs.  
Although important to rehabilitation, the significant methodological differences that exist 
across studies undermine attempts to draw definitive conclusions on the efficacy and differential 
benefits of SGAs to cognition in schizophrenia.  Two earlier quantitative reviews of published 
studies up to 1998 identified significant gains with SGAs in several cognitive domains including 
verbal fluency, vigilance, secondary memory, and visuomotor skills (Keefe, Silva, Perkins, & 
Lieberman, 1999; Harvey & Keefe, 2001).  Effect sizes, in terms of Cohen’s d, were typically 
within the range of 0.2 to 0.4 suggesting that the improvements may have limited clinical 
significance.  However, these earlier reviews were hampered by the relatively small number of 
double blind, random assignment studies that had been carried out prior to 1998, limited 
availability of data on olanzapine, and complete absence of data on quetiapine.  Since 1998 the 
results of over 20 studies involving SGAs including several large scale NIMH and industry 
sponsored clinical trails have been released and there is now a substantial pool of data on 
olanzapine’s effects on cognition and results from several investigations of quetiapine (Bilder et 
al., 2002; Harvey, Green, McGurk, & Meltzer, 2003; Purdon et al., 2001; Velligan et al., 2002).   
The larger number of studies now available for review permits a more thorough 
investigation of the cognitive improvements associated with SGAs.  Specifically, enough studies 
now exist to allow an identification of potential differences between treatments.  Although 
several investigations have directly compared medications within the SGA class, with few 
exceptions, (e.g. Harvey et al., 2003), interpretation of the results have been limited by the small 
number of subjects included in treatment groups (Purdon et al., 2000; Bilder et al., 2002).  By 
quantitatively analysing effects across studies, meta-analysis may help to overcome these sample 
size limitations, and help identify possible differences between treatments with respect to their 
effects on cognition. 
The large number of studies that have been reported since 1998 also make it feasible to 
examine the effects of relevant methodological characteristics, such as medication blind, random 
assignment of subjects, and study duration.  Earlier reviews have stressed the importance of 
controlling for these variables to protect against experimenter bias and demand characteristics.  
However, quantitative comparisons between studies that included these design features and those 
that did are lacking.   
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A meta-analysis of SGA studies may also be useful for addressing issues associated with 
baseline medications status and practice effects.  Several investigators have speculated that the 
cognitive improvements observed with SGAs may, in part, represent practice effects associated 
with repeated exposures to neuropsychological test batteries and an avoidance of derogatory 
effects associated with FGAs (Carpenter et al., 2002; Purdon et al., 2002; Purdon et al., 2003; 
Tandon, Milner, & Jibson, 1999).  Specifically, several FGA vs. SGA clinical trials have been 
criticized for using doses within the FGA arm that are too high, thus impairing cognition within 
the FGA comparator arm, or at least limiting the degree of improvement expected from retesting 
alone, and falsely identifying gains with SGAs, that presumably do not have similar negative 
effects on cognition.  In the case of within subjects switch studies, the absence of an unmedicated 
baseline assessment does not rule out a similar possibility that the improvements observed 
following a switch to an SGA treatment reflect a release from the adverse effects associated with 
FGAs rather than a novel enhancement of cognition.  Support for these contentions comes from a 
recent two-year investigation of risperidone versus low dose haloperidol (Green et al., 2002) and 
repeated demonstrations of a complete absence of improvement in the FGA comparator arms of 
several recent clinical trials (Bilder et al., 2002; Purdon et al., 2000).   
At present, over 40 studies have reported on the effects of clozapine, olanzapine, 
risperidone and quetiapine on a wide range of neuropsychological tests. The studies were entered 
into a meta-analysis to (1) evaluate and extend the findings of the earlier meta-analyses, (2) 
identify any differences between SGA medications on cognitive processes, (3) identify study 
characteristics that might be relevant to demonstrations of cognitive change, and (4) attempt to 
demarcate the cognitive benefits of SGAs, if they exist, from those that might be attributed to 
practice effects. 
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CHAPTER II 
 
METHODS 
Literature Search 
 
Relevant articles were identified through extensive literature searches of computerized 
databases including PsycInfo, Medline, and Dissertation Abstracts.  Key search terms included 
Schizophrenia, Cognition, Neuropsychology, Neurocognition, Clozapine, Olanzapine, 
Risperidone, and Quetiapine.  In addition, the bibliographies of several earlier reviews were 
examined (Keefe et al., 1999; Meltzer & McGurk, 1999; Purdon, 1999; Purdon, 2000; Harvey et 
al., 2001).  To ensure that the most recently published articles were included, the online table of 
contents and upcoming articles sections of the American Journal of Psychiatry, Archives of 
General Psychiatry, Biological Psychiatry, British Journal of Psychiatry, Schizophrenia 
Research, Neuropsychopharmacology, and Psychopharmacology web sites were reviewed for 
relevant articles.  Also, the authors of abstracts pertaining to cognition and treatment presented at 
the most recent international conference devoted to schizophrenia research (Schizophrenia 
Research, 2002) were contacted to solicit preprints of manuscripts accepted for publication but 
not yet in print.   
 Studies were included in the current meta-analysis if they met the following criteria: 1) 
inclusion of patients with a diagnosis of schizophrenia or schizoaffective disorder as outlined in 
DSM-III, DSM-III-R, DSM-IV, or ICD-9, ICD-10; 2) prospective study design with a baseline 
assessment and at least one follow-up assessment; 3) trial duration of at least 1 week; 4) no 
antipsychotics, aside from the study medications were administered; 5) a baseline sample size of 
at least 10; 6) results of neuropsychological change to treatment were reported for at least one of 
the common tests listed in Table 1; and 7) the study was published or ‘in press’ in a peer 
reviewed  journal.  Investigations of geriatric, adolescent (age <18 yrs), or high-risk populations 
were not included.   
 
Coding of Study Characteristics 
 
Studies were coded for author and year of publication, schizophrenia sub-type 
classification, baseline medication status, medication blind, random assignment, trial 
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medications, total subjects enrolled and the number completing the trial, trial duration, use of 
alternate neuropsychological test forms when applicable, and mean trial medication dosages.  
 Schizophrenia sub-type classification was based on explicit descriptions contained in 
each publication and consisted of three classifications: general schizophrenia, early phase, or 
treatment refractory.  Medication blind was coded as double blind or open label.  Open label 
extensions to double blind studies were not included in this analysis with one exception (Smith et 
al., 2001) because the within-group results were not reported for the end of the double-blind 
phase.  The number of subjects who completed the study was defined as the total number of 
subjects that completed the trial.  In addition, if a study reported statistics based on the last-
observation-carried-forward (locf) method, then these values were used to calculate effect sizes 
and the number of subjects completing at least one follow-up assessment was also reported. 
 
Neuropsychological tests and Domains 
 
An earlier meta-analysis of neurocognitive deficits in schizophrenia calculated effect 
sizes for individual neuropsychological tests rather than combining tests into domain scores 
(Heinrichs et al., 1998).  For comparison purposes, the same method was utilized in the current 
set of meta-analyses, although in several cases highly similar tests were combined into a single 
measure (e.g. verbal list learning).  In addition, composite domains scores have also been 
calculated by averaging effect sizes within studies across tests that putatively tap similar skills.  
Thus, each study contributed at least one effect size for each neuropsychological test and 
cognitive domain.  Both the effect sizes for the domains and individual tests are reported.  The 
construction of the domains reported here was based upon prior reviews and earlier studies that 
utilized large cognitive batteries, contemporary neuropsychological domain constructs, and 
cognitive domains identified as being especially relevant to outcome in schizophrenia (Purdon et 
al., 2000; Purdon et al., 2001; Green et al., 2002; Bilder et al., 2002; Heaton et al., 2001; Harvey 
& Keefe, 2001).  The tests and domains are listed in Table 1. 
The Vigilance domain included the Continuous Performance/Attention Test (CPT), 
Stroop Test (Stroop color-word), and Trailmaking A Test (TMA).  An aggregate score across 
both visual and auditory test versions was used for the CPT score.   This domain is linked to 
several dimensions of outcome (Green et al., 2000). 
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The Working Memory domain consisted of the Verbal Working Memory and Spatial 
Working Memory scores.  The Verbal Working Memory measure included the Digit Span, Digit 
Span Distraction, Paced Auditory Serial Addition, Letter-Number Span, and Consonant Trigrams 
tests.  The Spatial Working Memory measure included the Visual Span subtest of the WAIS-
R/III and the Spatial Working Memory Test (Meltzer et al., 1999; Green et al., 2002; Harvey et 
al., 2003). 
The Learning domain consisted of the Rey Serial Design Learning Test (RDLT), 
paragraph recall tests (LM I; WMS-R/III Logical Memory I or the Story Recall Test), verbal list 
learning tests (VLL I; California, Crawford, Hopkins or Rey Verbal Learning tests, or the 
Bushcke Selective Reminding Test), and visual reproduction tests (VR I; WMS-R/III Visual 
Reproduction subtest, the Rey-Osterith/Taylor Complex Figure Test, or the Benton Visual 
Retention Test). 
The Cognitive Flexibility & Abstraction domain consisted of the WCST (perseverate 
errors or percent perseverative errors score) and the WAIS-R/III Similarities subtest. 
The Processing Speed domain included the Digit Symbol/Modalities Test, Trailmaking B 
(TMB), and the Wechlser Intelligence Scale for Children-Revised/III (WISC-R/III) Mazes 
subtest.  This domain is associated with several dimensions of outcome. 
The Verbal Fluency domain consisted of a single measure that was calculated by 
combining the Controlled Oral Word Association and Category Instance Generation tests.  
Verbal Fluency is strongly correlated with outcome measures of community/daily activities. 
The Visuospatial Processing domain included the WAIS-R Block Design subtest (BD), 
the Rey-Osstereith/Taylor Complex Figure Test copy score (CFTc) and a visual organization 
(VOT) score derived from either the Hooper Visual Organization Test, Mooney Face Closure 
Test, Benton Judgment of Line Orientation, or Line Drawing tests. 
The Motor Skill Domain included the Finger Tapping Test (FTT) and a manual dexterity 
score consisting of either the Grooved Pegboard Test or the Pin Test (GPB/PIN).  
  The Delayed Recall domain included a visual recall score (VR II; WMS-R Visual 
Reproduction II or the delayed RCFT), a verbal recall score (LM II; WMS-R Logical Memory II 
or the delayed Story Recall Test), and a verbal list learning score (VLL II; delayed free recall 
scores from the verbal list learning tests described above). 
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Calculation of Effect Sizes and Data Analysis 
 
Typically, meta-analyses only include double-blind studies that randomly assigned 
subjects to either a control group or an active treatment group.  However, this approach would 
overlook a substantial body of evidence from open-label and single sample studies that may be 
relevant to the demonstration of cognitive change from SGA treatments.  In an attempt to 
preserve scientific rigor without omitting potentially important results, two analyses were 
undertaken, the first with a conservative approach to the published literature and the second with 
less conservative restrictions.       
 
Analysis One 
The first analysis included only reports from double-blind comparisons of FGAs and 
SGAs that randomly assigned patients to treatment.  Hedges’ g was used to estimate effect size 
by computing the difference between the post-treatment means of SGA and FGA groups, divided 
by their pooled standard deviation.  Where group means and standard deviations were not 
explicitly reported, Hedges’ g was calculated using appropriate alternative methods based on t or 
F statistics as outlined by Rosenthal (1994).  Where the t or F statistics were also not reported, 
data were solicited from the original study authors.  A weighted average effect size estimate was 
calculated for each neuropsychological test and domain by combining data from all studies that 
examined cognitive change to clozapine, olanzapine, risperidone, or quetiapine.  In cases where a 
study included more than one SGA arm, in addition to an FGA control, or multiple dosing arms, 
the SGA arms were treated as separate samples and effect sizes for each arm were calculated.  
Effect sizes were combined according to the fixed effects model described by Shadish & 
Haddock (1994).  Briefly, each effect size was weighted by the inverse of its associated variance 
such that effect sizes calculated from studies with larger sample sizes contributed more to the 
overall effect size when combined.  A weighted average effect size and corresponding 95% 
confidence interval (CI) were then calculated.  CI’s that excluded zero were considered 
significant.  Positive values indicate improvement and negative values indicate a decline in 
performance.  To assess the relevance of predefined moderator variables, a measure of effect size 
homogeneity, the Q statistic, was also calculated for each neuropsychological domain.  The Q 
statistic has a chi-square distribution with k-1 degrees of freedom, where k is the number of 
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effect sizes being combined.  The critical alpha for the Q statistic was set at .05.  When the 
assumption of homogeneity was rejected the effect sizes were combined using the random 
effects model and an analysis of moderator variables was undertaken (Hedges & Vevea, 1998).  
In the moderator variable analysis, the Q statistic was partitioned into a between groups 
component, QBET, and a within groups component, QW.  A moderator variable was considered 
significant if it effectively separated the effect sizes into separate categories (i.e. QBET was 
significant) that did not have significant within group variation (i.e. QW was not significant).  
The R2 value was also calculated for each significant moderator variable to assess the strength of 
the relationship between moderator and dependent variables. Moderator variables included the 
coded study characteristics of baseline medication status (medicated vs. unmedicated) and 
schizophrenia sub-type classification (early phase combined with general, vs. treatment 
refractory).  In addition, Pearson’s R correlations were carried out for each domain to examine 
possible relationships between effect sizes and trial duration or effect sizes and FGA comparator 
drug dose.  To avoid violations of independence in the moderator variable analysis, average 
effect sizes were calculated across groups for the three studies that examined cognitive change in 
more than one SGA treatment or dosing arm (Bilder et al., 2002; Velligan et al., 2002; Purdon et 
al., 2000). 
 
Analysis Two 
The second analysis included all prospective studies of cognitive change that evaluated 
clozapine, olanzapine, risperidone, or quetiapine.  The second analysis included all prospective 
studies, including both the double-blind and the open label studies, regardless of whether or not 
participants were randomly assigned to treatment.  Investigations of cognitive change following 
a shift from one SGA to another were not included.  A one sample, dependent measures index of 
effect size analogous to Hedges’ g, the mean change score divided by its standard deviation, was 
used as the estimate of effect size (Rosenthal, 1994).  Paired t-tests or alternative repeated 
measures values were available to calculate an effect size for the majority of studies.  In studies 
that did not report change scores, an estimate of effect size was derived using the procedure of 
Smith, Glass, and Miller (1980), which estimates change from the pre-treatment and post-
treatment group means, divided by the standard deviations reported in the original manuscript, 
and adjusted for test-retest correlations provided in a compendium of neuropsychological tests 
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(Spreen & Strauss, 1998).  Weighted effect sizes, 95% CIs, and Q statistics were then calculated 
overall for each neuropsychological measure and domain, and again within each medication 
group.  As in Analysis One, when the Q statistic was rejected, effect sizes were combined 
according to the random effects model. 
The effect sizes obtained in Analysis Two were compared to effect sizes obtained from 
longitudinal studies of the stability of neuropsychological function in schizophrenia and controls 
in order to examine the contribution of practice effects to the improvements associated with SGA 
medications (Heaton et al., 2001; Sweeney, Haas, Keilp, & Long, 1991; Dikmen, Heaton, Grant, 
& Temkin, 1999; Basso, Bornstein, & Lang, 1999; Basso, Lowery, Ghormley, & Bornstein, 
2001).   These studies were used because a) they examined practice effects across test-retest 
intervals comparable to studies of SGAs (i.e. 6 to 18 months), b) included comprehensive test 
batteries that overlapped considerably with the tests examined in the current meta-analysis and 
provided enough data to calculate effect sizes, and c) included an appropriate number of subjects 
(range 39-384).  In general, investigations of the longitudinal stability of neuropsychological 
deficits in schizophrenia have indicated that practice effects across repeated administrations of 
neuropsychological tests are very similar to those observed in healthy controls (e.g. Heaton et al., 
2001; Hoff et al., 1999; Censits, Ragland, Gur, & Gur, 1997; Rund, 1998).  The following 
practice related effect sizes were obtained from the above studies: Vigilance ES=0.27, Working 
Memory ES=0.12, Learning ES=0.32, Processing Speed ES=0.35, Cognitive Flexibility and 
Abstraction ES=0.27, Verbal Fluency ES=0.16, Visuospatial Skill ES=0.36, Motor Skill 
ES=0.15, Delayed Recall ES=0.20.  These effect sizes were compared to those obtained from 
studies of SGAs and if the 95% CI identified for a given domain excluded the practice effect 
size, the improvement was considered significantly greater than that expected from practice 
alone. 
Analysis Two had a sufficient number of studies to allow for a more comprehensive 
examination of the influence that study characteristics might have on effect sizes and 
comparisons between SGA medications.  Comparisons of the dichotomous variables study blind 
or random assignment (controlled vs. uncontrolled), baseline medication status (unmedicated vs. 
medicated), and schizophrenia sub-type classification (early phase combined with general, vs. 
treatment refractory) were carried out as described in Analysis One (by partitioning the Q 
statistic into between and within groups components) for each cognitive domain.  The variables 
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study blind and random assignment were collapsed into a single variable due to the fact that 
almost every study that was double blind also randomly assigned subjects to treatment.  Thus, in 
order to avoid the redundancy of carrying out two comparisons, studies that included at least one 
of these features in their design were coded as controlled and those that did not include either 
were coded as uncontrolled.  Pearson’s R correlations were carried out to examine relationships 
between domain effect sizes and study duration.   
In addition, contrasts between medication groups were carried out for each cognitive 
domain.  Group differences were examined in the same manner as moderator variables, by 
partitioning the Q statistic into a between and within groups component where the between 
groups component reflects the difference between medication groups and the within groups 
component represents an overall measure of the variability within medication groups.  In cases 
were QBET was significant, pairwise contrasts were carried out to identify specific differences 
between medication groups.  A weighted within medication group effect size was not included in 
the pairwise contrasts if it was calculated under the random effects model.   
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CHAPTER III 
 
RESULTS 
Analysis One 
Study Demographics 
Twelve studies were included in analysis one.  Effect sizes for one study could not be computed 
from the information provided by the author (Kern et al., 1998).  Two studies included more than 
one SGA treatment arm (Purdon et al., 2000; Bilder et al., 2002) and one study randomized 
subjects to two separate dose groups of the same SGA treatment (Velligan et al., 2002).  
Schizophrenia sub-type classification for the 12 studies was early phase (n=1), general (n=5), 
and treatment refractory (n=6).  Baseline medication status included unmedicated (n=4) and 
medicated (n=8).  After excluding four reports from the same study because of discrepancies in 
the reported number of enrolled subjects (Green et al., 1997; Kern et al., 1998; Kern et al., 1999; 
McGurk et al., 1997), the eight remaining (independent) studies reported retention of 43% to 
93% of the enrolled patients.  As expected, attrition was lower in studies with a short duration of 
treatment and retention improved to a range of 55% to 93% of enrolled subjects when the last 
observation was carried forward for analysis. 
Trial durations ranged from 4 weeks to 104 weeks and most studies included a variety of 
neuropsychological tests.  Practice effects were relevant to instruments used in nine of the twelve 
studies, but only four of the nine included alternate forms in the experimental design ((Purdon et 
al., 2000; Purdon et al., 2001; Ljubin, Zakic, Mimica, Folnegovic-Smalc, & Makaric, 2000; 
Smith, Infante, Singh, & Khandat, 2001).  The range of average doses used for each medication 
was consistent with doses recommended in the various product monographs; clozapine (410.5-
498 mg), olanzapine (11-30 mg), risperidone (5.7-11.3 mg), and quetiapine (300-600 mg).  The 
average dose used in the haloperidol control arms ranged from 4.5-37.9 mg. 
 
Neuropsychological Test Effect Sizes 
SGAs improved cognitive function more than FGAs in the Learning (ES=0.33), 
Processing Speed (ES=0.27), Verbal Fluency (ES=0.26), and Delayed Recall (ES=0.24) 
domains.  Significant improvements were observed on all tests grouped within the Learning 
domain (ES=0.32-0.73), both tests of Processing Speed (DSST=0.41, TMB=0.19), and two tests 
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within the Delayed Recall domain (VLL II=0.35, VR II=0.31).  Additional improvements on 
specific tests were observed within the Working Memory (Spatial Working Memory: ES=0.39) 
and Motor Skills (FTT: ES=0.30) domains (see Table 2). The assumption of homogeneity was 
not violated on any domain score and only one test, DSST, was calculated under the random 
effects model do to the presence of significant heterogeneity amongst the set of effect sizes that 
comprised the combined weighted effect size for this test, ?2df=9=17.36, p=.027.   
Study duration was significantly inversely correlated with the Learning and Cognitive 
Flexibility and Abstraction domain effect sizes, Pearson’s r=-.87, p<.025, and r=-.92, r<.005 
respectively.  It was apparent however, that the correlations were heavily influenced by the 
Green et al. (2002) study that was considerably longer, 104 weeks, than the remaining studies.  
After removal of this study, a positive correlation between study duration and Cognitive 
Flexibility and Abstraction domain effect size was present, r=.90, p<.016.  Comparator drug dose 
was not significantly correlated with any cognitive domain, however, the correlations for 
Vigilance, Learning, Cognitive Flexibility and Abstraction, and Processing Speed effect size 
were all greater than .63, p<.18, indicating that studies utilizing higher doses of haloperidol 
tended to produce larger SGA effect sizes for these domains. 
  
Analysis Two 
Study Demographics 
Forty-one studies met the criteria for inclusion in analysis two.  The schizophrenia sub-type 
classification included early phase (n=4), general (n=18), and treatment refractory (n=19) 
patients.  Baseline medication status included unmedicated (n=11), medicated (n=29), and 
unknown (n=1).  Eighteen studies randomly assigned patients to treatment arms and fifteen were 
double blind investigations.  Two studies were single blind.  Among the studies that were not 
included in Analysis One, the percentage of subjects completing the trials ranged from 45% to 
100%.  As expected the average percentage was high, 82%, possibly reflecting the tendency for 
less controlled studies to infrequently report the number of subjects initially screened or enrolled 
in a study.  Follow-up assessments ranged from 1.5 weeks to 3 years and the size of the test 
batteries ranged from a single measure to 18 tests.  Thirty-two studies used neuropsychological 
tests for which alternate forms were available, but only 11 of the 32 included alternate forms in 
the experimental design.  The mean and range (in parentheses) of doses under double-blind (DB) 
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conditions tended to be lower than the open label (OL) doses in studies of clozapine: DB=454.3 
(410.5-498), OL=459 (200-719), and quetiapine: DB=456.1 (300-600), OL=479.3 (319.3-750), 
whereas the reverse was true for olanzapine: DB =20.3 (11-30), OL=18 (12-35.5), and 
risperidone: DB=6.8 (5-11.3), OL =5.5 (2.2-8.95).  
 
Neuropsychological Test Effect Sizes 
Second Generation Treatments 
The information provided by the authors of two studies was insufficient to allow 
calculation of effect sizes (Meltzer, 1992; Kern et al., 1998).  The second analysis showed a 
more robust SGA benefit on cognitive skills than the more conservative first analysis (see Table 
3).  All cognitive domains demonstrated a substantial improvement on SGA medications 
compared to an FGA or medication free baseline.  The weighted effect sizes for the nine domains 
ranged from 0.18 to 0.37.  Similarly, significant improvements were observed on virtually every 
test and the effect sizes ranged from a low of 0.14 on the WCST to a high of 0.61 on the DSST.  
The weighted effect size for one domain, Vigilance, was calculated under the random effects 
model due to the presence of significant heterogeneity, ?2df=27=44.37, p<.019. 
 The effect sizes for each domain were compared to the effect sizes estimated from 
practice effects (see Figure 1).  The weighted effect sizes for Working Memory (95% CI=0.17-
0.39), Verbal Fluency (95% CI=0.28-0.46), Motor Skills (95% CI=0.18-0.56), and Delayed 
Recall (95% CI=0.27-0.47) were significantly greater than the practice effects ESs. 
 
Moderator Variables 
Schizophrenia sub-type classification was not significantly associated with any cognitive 
domain nor was study duration significantly correlated with any domain effect size.  The 
moderator variable control was significantly associated with both Verbal Fluency and Processing 
Speed indicating that studies that did not randomize subjects to treatments or were open label 
produced different effects sizes compared to those that included either of these features in their 
designs.  Processing Speed effect sizes calculated from controlled studies were significantly 
smaller than those obtained from open label or non-random assignment studies, ES=0.26 vs. 0.47 
(QBET=5.44, p<.020, QW=44.89, p<.175, R2=.11).  Recalculation of the weighted effect size for 
all SGAs indicated that the Processing Speed effect size remained significantly greater than zero 
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after excluding studies that did not randomly assign subjects to treatment or were open label 
(95% CI=0.15 – 0.37). Within medication group effect sizes decreased for clozapine, 
risperidone, and quetiapine (ESs=0.28, 0.19, and 0.24 respectively), and slightly increased for 
olanzapine (ES=0.56).  The olanzapine and risperidone effect sizes remained significantly 
greater than zero after exclusion of the less controlled studies; however, the clozapine and 
quetiapine effect sizes did not.  
In the case of Verbal Fluency, the weighted effect size for controlled studies was also 
significantly smaller than that observed in uncontrolled studies, ES=0.25 vs. 0.45 (QBET=4.13, 
p<.043, QW=30.30, p<.451, R2=.12).  The weighted effect size from controlled studies remained 
greater than zero though, (95% CI=0.13 – 0.37).  Recalculation of within medication group effect 
sizes after excluding the uncontrolled studies indicated that the weighted effect sizes for 
clozapine, olanzapine, and risperidone decreased slightly (ESs=0.41, 0.23, and 0.04 
respectively), and increased marginally for quetiapine (ES=0.68).  The effect sizes for 
olanzapine, clozapine, and quetiapine still remained significantly greater than zero.  
 
Comparison of Second Generation Medications  
Pairwise comparisons between medication groups were carried out on each cognitive 
domain.  Significant differences between medication groups were observed on the Vigilance 
(QBET=17.74, p<.0005, QW=26.63, p<.322, R2=.40) and Verbal Fluency (QBET=14.41, p<.003, 
QW=20.03, p<.951, R2=.42) domains.  Follow-up contrasts within the Vigilance domain revealed 
a significant advantage for quetiapine, relative to clozapine (?2df=1=8.51, p=.004) and risperidone 
(?2df=1=13.10, p=.0003), and a significant advantage of olanzapine, relative to risperidone 
(?2df=1=7.97, p=.005).   
Pairwise contrasts within the Verbal Fluency domain indicated that quetiapine improved 
performance to a greater extent than both risperidone (?2df=1=11.09, p=.0009) and olanzapine 
(?2df=1=4.30, p=.039) and clozapine improved performance to a greater extent than risperidone 
(?2df=1=9.19, p=.003).  The pairwise contrasts were repeated after exclusion of the uncontrolled 
studies due to the fact that this moderator variable was associated with verbal fluency effect 
sizes.  After excluding the less controlled studies, the quetiapine vs. risperidone and quetiapine 
vs. olanzapine contrasts remained significant (?2df=1=10.09, p=.0009 and ?2df=1=4.30, p=.039) as 
did the clozapine vs. risperidone contrast (?2df=1=9.19, p=.003).  
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Within Group Effect Sizes 
Clozapine was associated with significant improvements from baseline to endpoint on 
seven of the nine domains examined.  These included improvements in Working Memory 
(ES=0.25), Learning (ES=0.31), Processing Speed (ES=0.35), Cognitive Flexibility and 
Abstraction (ES=0.25), Verbal Fluency (ES=0.44), Motor Skills (ES=0.64), and Delayed Recall 
(ES=0.25).  After comparison to anticipated practice effect values, only the Verbal Fluency (95% 
CI=0.28-0.60) and Motor Skills (95% CI=0.29-0.99) domain effect sizes remained significant 
(see Figure 2). 
Olanzapine also significantly improved performance in seven of the nine domains 
examined.  These included improvements in the Vigilance (ES=0.45), Working Memory 
(ES=0.33), Learning (ES=0.43), Processing Speed (ES=0.57), Verbal Fluency (ES=0.28), 
Visuospatial Skill (ES=0.66), and Delayed Recall (ES=0.46) domains.  The Processing Speed 
effect size was calculated under the random effects model, ?2df=7=16.75, p<.020.  When the 
practice effect values were used as a basis of comparison, only the Working Memory (95% 
CI=0.14-0.51) and Delayed Recall (95% CI=0.26-0.66) domains reached significance (see 
Figure 2). 
Risperidone was associated with significant effect sizes in 5 of the 9 cognitive domains.  
These included significant improvements in Working Memory (ES=0.24), Learning (ES=0.39), 
Processing Speed (ES=0.30), Visuospatial Skill (ES=0.39), and Delayed Recall (ES=0.46).  The 
Delayed Recall effect size (95% CI=0.26-0.46) was significantly greater than the practice effect 
size value (see Figure 2). 
Within the Quetiapine group, significant improvements were observed in the Vigilance 
(ES=0.73), Processing Speed (ES=0.35), and Verbal Fluency (ES=0.63) domains.  There was 
significant variability among the effect sizes that made up the weighted Delayed recall domain 
effect size, ?2df=2=6.51, p<.039, therefore, the effect size for this domain was calculated under the 
random effects model.  The improvements in Vigilance (95% CI=0.43-1.03) and Verbal Fluency 
(ES=0.36-0.90) were greater than that expected from practice alone (see Figure 2).  The results 
for quetiapine should be interpreted cautiously given that the effect sizes for several domains 
included relatively few studies and, in the case of visuospatial skill, were based on a single study. 
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CHAPTER IV 
 
DISCUSSION 
 
The findings from the current set of meta-analyses indicate that SGAs improve 
performance in a number of cognitive domains.  The results obtained from the current meta-
analysis of 12 double blind, random assignment studies supported the findings of the earlier 
meta-analysis of five double blind studies that identified significant cognitive advantages with 
SGAs relative to FGAs.  The greater number of studies included in the current meta-analysis of 
double blind, random assignment studies allowed for a finer delineation of the improvements and 
indicates that, relative to FGAs, SGAs improve performance on tests of learning and delayed 
recall, processing speed, and verbal fluency.  More subtle benefits were also observed on aspects 
of working memory and motor skill.  In general, there was not strong evidence that sample 
characteristics, such as treatment responsive vs. refractory or baseline medication status, had a 
prominent effect on cognitive change to SGA treatment in double-blind, random assignment 
studies.  There was evidence that studies with a longer duration are associated with greater 
improvement on tests of cognitive flexibility and abstraction.  There was also limited evidence 
that studies utilizing larger doses of haloperidol resulted in larger effect sizes with SGA 
treatment.  Although correlations between haloperidol dose and effect size with SGA treatment 
was positively correlated with improvement in several domains, none reached statistical 
significance.  Nonetheless, it is a noteworthy observation and suggests that some of the benefits 
observed with SGA treatments may, in part, relate to the larger doses of haloperidol used and 
associated blunting of cognitive performance. 
The inclusion of investigations with single treatment arms and open label designs 
supported the benefits from SGA treatments reported in double blind, random assignment trials 
and extended the potential improvements to a wider array of neuropsychological tests.  Indeed, 
every cognitive domain and virtually every neuropsychological test significantly improved with 
SGA treatment.  The effect sizes for domains ranged from 0.18 to 0.37 and are remarkably 
consistent with Harvey & Keefe’s (2001) review of 20 studies.  For example, Harvey & Keefe’s 
(2001) review identified improvements, in terms of Cohen’s d, of 0.18 and 0.37 for executive 
functions and delayed recall respectively.  The results reported here for cognitive flexibility and 
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abstraction and delayed recall were 0.18 and 0.39. 
In contrast to prior reviews, the current meta-analysis carried out pairwise contrasts 
between SGAs in order to identify possible differences between treatments.  No medication 
appeared superior or inferior to the other medications across all domains, but several differences 
emerged in two domains, Vigilance and Verbal Fluency.  The results were generally consistent 
with predications derived from the assumption that lower dopamine activity and increased 
serotonin activity may be related to cognitive benefits from novel agents, but the results were not 
entirely consistent with the assumption that increased anticholinergic properties might limit gains 
in memory and attention.  Risperidone, presumed to have the greatest activity at dopamine 
receptors (Seeman, 2002), showed the least beneficial profile on measures of vigilance and 
verbal fluency, being outperformed by quetiapine and olanzapine on vigilance, and quetiapine 
and clozapine on verbal fluency.  The differences were quite robust and ranged from 0.3 to 0.5 
standard deviations.  Clozapine, presumed to have substantial inherent anticholinergic properties, 
did not significantly improve any test of vigilance and it resulted in less improvement than 
quetiapine on this domain.  Moreover, although clozapine significantly improved delayed recall, 
these gains were significant on only one test, VLL II, and overall improvement in this domain 
was markedly less than that observed in the olanzapine and risperidone groups.  However, 
despite the presumption of significant inherent anticholinergic activity, olanzapine did not 
conform to this model.  Olanzapine led to medium to large gains on tests of vigilance and 
delayed recall.  It thus appears that, at least at the dosages used here, olanzapine’s anticholinergic 
effects may not be sufficient to impair memory or attention.  These data tend to converge on the 
absence of central anticholinergic symptoms or cognitive impairment observed in patients with 
Alzhiemer’s disease treated with very low doses of olanzapine (Kennedy et al., 2001; Street et 
al., 2000) and the lower incidence of cholinergic-related side effects and serum anticholiergic 
levels observed with olanzapine relative to clozapine (Eschweiler et al., 2002; Chengappa et al., 
2000).   
Analysis Two also examined the influence that moderator variables might have on effect 
sizes associated with SGA treatment.  No widespread moderator effects were observed but a few 
test-specific effects were apparent.  Studies that did not randomly assign subjects to treatment or 
were open label reported larger verbal fluency and processing speed effect sizes than studies that 
included either of these features in their design.  Although the effects were modest and accounted 
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for a relatively small fraction of the variance, particularly in comparison to the differences 
between treatment groups, these observations are important and indicate that factors such as 
double blind and random assignment need to be considered when evaluating the literature on 
cognitive change to pharmacological treatments in schizophrenia.  Overall, the results of the 
moderator variable analyses speak to the consistency of the results across different studies of 
SGAs suggesting that SGA benefit is not strongly influenced by schizophrenia sub-group 
classification, baseline medication status, or trial duration.  Due to the small number of 
observations within each medication group, we were not able to fully explore the effect of 
moderator variables within each treatment group.  This is unfortunate particularly in regard to 
duration of treatment, where longer trials of risperidone have failed to confirm the benefits from 
short duration trials, and where longer duration trials of olanzapine have produced greater benefit 
than shorter duration trials (Purdon et al., 2000; Green et al., 2002; Bilder et al., 2002; Harvey et 
al., 2003).  In addition, the doses of SGAs used may also influence cognitive change.  For 
example, larger doses of quetiapine have been associated with greater cognitive improvement 
(Velligan et al., 2002).   
The moderator analysis is an effective method for detecting systematic variability 
between different studies of cognitive change to novel treatments, but it does not allow an 
assessment of more systematic challenges to the validity of the cognitive benefits reported from 
SGAs relative to FGAs or to the validity of differential benefits within the SGA class.  The 
adjunctive use of anticholinergic medications and the failure to control for cognitive 
improvements that result from prior exposure to neuropsychological tests represent the two most 
problematic challenges to the validity of the SGA benefit.  For example, although the double-
blind design with random assignment to parallel treatment arms represents the gold standard for 
demonstrating differential efficacy, it is open to the confounding effects of a systematic 
differential utilization of adjunctive anticholinergic medications.  In all studies with an FGA 
control arm, emergent extra-pyramidal symptoms will result in adjunctive treatment that will 
typically include an anticholinergic medication that will likely interfere with cognitive skills, 
particularly attention and memory.  Although reports of differential efficacy from double-blind 
trials have occasionally included post-hoc analyses after stratification by anticholinergic use (e.g. 
Purdon et al., 2000), this is not the norm, and the relatively small sample sizes produced by 
stratification often renders the power of the study insufficient to detect an anticholinergic effect 
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on cognitive change.   
A second systematic artifact relates to the possibility of practice effects that could occur 
on neuropsychological measures that are repeatedly administered to the same subject.  In the 
double-blind studies, practice effects would be expected in both the SGA and the FGA treatment 
arms, and thus a relative advantage of SGAs would not likely be related to practice effects alone.  
However, this inference relies on the unsupported assumption that there will be no interaction 
between treatment and practice (Carpenter et al., 2002).  To the contrary, emerging evidence 
suggests that first generation treatments may have a detrimental effect on new learning that may 
limit the benefit of repeated exposure to the same materials (Blyler & Gold, 2001).  For example, 
a change to clozapine from FGAs resulted in improvement in procedural learning that may relate 
to a release from impairment caused by the FGA (Purdon et al., 2002), and intact procedural 
learning in unmedicated patients was compromised by 6 months’ treatment with haloperidol but 
not olanzapine (Purdon et al., 2003).  Similar demonstrations of a preservation of procedural 
learning with olanzapine and clozapine compared to the apparent loss of procedural learning 
induced by haloperidol, and perhaps risperidone, (Bedard et al., 1996; Bedard et al., 2000; 
Stevens et al., 2002) all tend to support the view that some of the improvements with SGAs 
might result from an avoidance of derogatory effects associated with FGAs rather than a novel 
enhancement of cognition.  We undertook an exploratory examination of this hypothesis in 
Analysis Two by comparing the effect sizes derived from studies of SGAs with those calculated 
from longitudinal investigations of practice effects in schizophrenia patients and controls.  After 
comparison to practice effects, the effect sizes for working memory, verbal fluency, motor skills, 
and delayed recall remained significant.  Specifically, clozapine improved verbal fluency and 
motor skills, olanzapine improved working memory and delayed recall, quetiapine improved 
vigilance and verbal fluency, and risperidone improved delayed recall.  Thus, it appears that 
although practice effects account for a significant portion of the cognitive improvements 
observed with SGAs, there are additional cognitive advantages with SGA treatments that exceed 
those expected from retesting alone.  Our confidence in this finding must be tempered though by 
an appreciation of the limitations of the method used to establish the postulated practice effect 
magnitudes in the current investigation.  Specifically, although longitudinal investigations of 
neuropsychological function in schizophrenia and controls do not report considerable differences 
in the degree of practice effects between groups and re-test intervals beyond three months do not 
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appreciably influence practice effects, the fact that the average practice effect values used here 
were based on test-retest intervals that were generally greater than 12 months in duration, 
whereas most cognitive change studies tend to be shorter, may have underestimated the true 
amount of improvement expected from practice (Heaton et al., 2001; Hoff et al., 1999; Censits et 
al., 1997; Dikmen et al., 1999; Basso, Bornstein, & Lang, 1999; Basso et al., 2001; Sweeney et 
al., 1991). 
 The improvements in cognitive performance with SGAs are in general encouraging, 
especially when the potential implications for socio-vocational re-integration are considered.  
The gains observed on tests of delayed verbal recall may be particularly relevant as this cognitive 
skill has been linked to three major dimensions of outcome including community/daily activities, 
social problem solving/instrumental skills, and psychosocial skill acquisition (Green, 1996; 
Green et al., 2000).  Furthermore, the differential patterns of cognitive improvement combined 
with the knowledge that specific cognitive skills are linked to separate dimensions of outcome 
might also suggest that second generation treatments may be differentiated from one-another 
based on their unique effects on outcome.  The strong gains observed in delayed recall with 
risperidone and olanzapine suggest that these treatments may be particularly effective at 
improving psychosocial skill acquisition.  Furthermore, the robust improvements in vigilance 
observed with quetiapine, and to a lesser degree olanzapine, suggest that these treatments might 
have additional benefits to functional outcome.  In contrast, clozapine’s rather limited effects on 
delayed recall, but significant effects on verbal fluency, suggest that it may have a greater impact 
on community/daily living skills.  Although direct evidence to test these predictions is limited, a 
recent double blind, random assignment study indicated that olanzapine improved quality of life 
based rating scales to a greater extent than risperidone (Gureje et al., 2003) and earlier 
investigations have indicated that olanzapine treated patients demonstrate greater improvement 
in work and social outcomes than haloperidol (Hamilton, Edgell, Revicki, & Breier, 2000).  Pilot 
data from an earlier investigation also support the positive effects of olanzapine on functional 
outcome (Noordsy & O'Keefe, 1999).  Similar improvements, relative to FGAs, in quality of life 
have also been reported for quetiapine (Velligan et al., 2003).  Also, a recent 2 –year, random 
assignment study examining suicide attempts in patients receiving either clozapine or olanzapine 
indicated that clozapine is more effective at reducing suicide attempts and suicide related 
hospital admissions than olanzapine (Meltzer et al., 2003).  One of the studies included in the 
  22
present analysis also examined functional outcome with clozapine treatment and although the 
outcome measure was restricted to discharge rates, the results are encouraging (Manschreck, 
Redmond, Candela, & Maher, 1999).  Similar, data on reduced relapse rates have been reported 
for risperidone (Chengappa et al., 1999; Csernansky, Mahmoud, & Brenner, 2002).   
The cognitive improvements to SGAs appear reliable, valid, and may be relevant to 
rehabilitation, but it is prudent to conclude this discussion with emphasis on the relatively small 
magnitude of the observed changes.  Schizophrenia patients typically score more than a standard 
deviation below healthy controls on many of the neuropsychological tests reviewed here 
(Heinrichs et al., 1998).  As a class, the SGAs improve all cognitive domains but the 
improvement is typically in the range of 0.20 to 0.40 standard deviations.  These results are 
further attenuated when compared to anticipated practice related improvements.  It is unlikely 
that the gains will be sufficient to return patients to the vocational level anticipated from their 
individual premorbid status.  Indeed, improvements less than one standard deviation may not 
have any effect on outcome (Bellack, Gold, & Buchanan, 1999).  However, the medication-
specific effects of particular SGAs on particular cognitive domains could be relevant to the 
design of individual treatment plans that take into account the patient’s premorbid intellect, 
unique profile of cognitive impairment, prior vocational achievements, and long term socio-
vocational aspirations.   
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Vigilance
Continous Performance Test CPT
Stroop Test (color-word score) Stroop
Trailmaking A TMA
Working Memory
Verbal Working Memory 
Spatial Working Memory 
Learning
Paragraph Recall\WMS-R Logical Memory (immediate) LM I
Verbal List Learning tests (learning trials) VLL I
Rey Design Learning Test RDLT
Visual Reproduction VR I
Cognitive Flexibility & Abstraction
Wisconsin Card Sorting Test (pers. errors) WCST
WAIS-R/III Similarities SIM
Processing Speed
Digit Symbol Substitution DSST
Trailmaking B TMB
WISC-R Maze Subtest WISC Maze
Verbal Fleuncy (COWA & CIGT) VF
Visuospatial Processing
Block Design BD
Complex Figure Test (copy) CFT
Visual Organization VOT
Motor Skills & Manual Dexterity
Finger Tapping Test FTT
Grooved Pegboard Test/PIN Test GPB/PIN
Delayed Recall
Paragraph Recall\WMS-R Logical Memory (delayed) LM II
Verbal List Learning tests (delayed free recall) VLL II
Visual Reproduction VR II
Table 1.  Neuropsychological Tests and Cognitive Domains
Abbreviation
  32
 
k N k N k N k N k N
2 43 2 36 3 73 2 30 9 182 0.11 -0.09 - 0.32 2.52 8
Stroop 1 19 1 10 -- -- 2 42 4 71 0.09 -0.26 - 0.44 0.55 3
TMA 1 24 1 26 2 54 -- -- 4 104 0.15 -0.12 - 0.43 1.59 3
CPT -- -- -- -- 1 19 -- -- 1 19 -0.07 -- -- --
1 24 2 46 4 87 1 11 8 168 0.17 -0.05 - 0.39 2.49 7
Verbal Working Memory 1 24 2 46 4 87 1 11 8 168 0.09 -0.13 - 0.31 3.04 7
Spatial Working Memory -- -- 1 20 2 39 1 11 4 70 0.39* 0.03 - 0.75 3.54 3
1 25 2 46 4 97 3 54 10 222 0.33* 0.14 - 0.53 6.10 9
LM I 1 25 2 46 2 46 1 11 6 128 0.35* 0.10 - 0.61 2.48 5
VLL I 1 24 2 46 4 97 3 54 10 221 0.32* 0.13 - 0.52 7.31 9
VR I 1 24 2 46 2 46 1 11 6 127 0.48* 0.22 - 0.73 3.48 5
RDLT -- -- 1 20 1 20 1 11 3 51 0.73* 0.30 - 1.15 0.65 2
2 42 3 56 4 93 3 54 12 245 0.27* 0.09 - 0.46 9.53 11
DSST
b
1 24 3 56 2 46 3 54 9 180 0.41* 0.08 - 0.74 17.36 9
TMB 2 42 2 46 4 93 3 54 11 235 0.19* 0.00 - 0.38 4.89 10
2 43 4 75 3 62 1 11 10 191 0.11 -0.10 - 0.32 7.48 9
SIM -- -- 2 30 1 20 1 11 4 61 0.29 -0.08 - 0.67 0.25 3
WCST 2 43 4 75 3 62 1 11 10 191 0.10 -0.11 - 0.31 7.47 9
2 42 2 65 3 65 3 54 11 226 0.26* 0.06 - 0.45 7.89 10
2 43 3 56 3 65 1 11 9 175 0.11 -0.10 - 0.34 8.38 8
BD 2 42 2 36 2 45 -- -- 6 123 0.09 -0.16 - 0.35 8.53 5
CFT -- -- 1 20 1 20 1 11 3 51 0.13 -0.28 - 0.55 4.59 2
VOT 1 19 1 20 1 20 1 11 4 70 0.34 -0.13 - 0.69 2.63 3
1 24 2 46 3 65 1 11 7 146 0.19 -0.05 - 0.43 7.08 6
FTT 1 24 2 46 2 46 1 11 6 127 0.30* 0.05 - 0.55 4.44 5
GPB/PIN -- -- 1 20 2 39 1 11 4 70 0.15 -0.20 - 0.51 6.13 3
2 43 1 26 2 50 2 43 7 170 0.24* 0.02 - 0.46 3.00 6
LM II 2 43 1 26 1 26 2 43 6 138 0.06 -0.18 - 0.62 2.42 5
VLL II 1 24 1 26 2 58 -- -- 4 108 0.35* 0.08 - 0.62 2.35 3
VR II 2 43 1 26 1 26 -- -- 4 95 0.31* 0.02 - 0.60 1.08 3
* Z-score > 1.96, p<.05.
 Random effects model, chi-square p-value < .05.
VIGILANCE
95% CI
Clozapine Olanzapine Risperidone Quetiapine
ES
VISUOSPATIAL SKILLS
Table 2: Neuropsychological Change with Second Generation Treatment: Analysis 1.
Overall Weighted Effect Size
dfQ Statistic 
Number of Effect Sizes (k) and Number of Subjects (N)
VERBAL FLUENCY
MOTOR SKILLS
DELAYED RECALL
WORKING MEMORY
LEARNING
COGNITIVE FLEXIBILITY & ABSTRACTION
PROCESSING SPEED
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k N ES k N ES k N ES k N ES k N ES
VIGILANCE 8 152 0.17 6 220 0.45* 9 313 0.10 5 95 0.73* 28 780 0.30*a
Stroop 3 55 0.18 3 40 0.80* 2 43 0.15 3 58 0.67a 11 196 0.44*a
TMA 4 83 0.20 4 194 0.36* 4 241 0.07 2 93 0.23 14 557 0.19*
CPT 1 14 -0.08 2 149 0.46* 5 188 0.22 2 33 0.90* 10 384 0.35*
WORKING MEMORY 8 160 0.25* 6 239 0.33* 9 281 0.24* 2 27 0.41 25 707 0.28*
Verbal Working Memory 8 160 0.24* 4 85 0.42* 8 156 0.25* 2 27 0.36 22 428 0.29*
Spatial Working Memory 1 18 0.46 5 213 0.34* 3 164 0.21 1 11 0.43 10 406 0.30*
LEARNING 10 221 0.31* 6 203 0.43* 7 225 0.39* 6 112 0.24 29 750 0.36*
LM I 5 95 0.53* 3 62 0.43* 4 71 0.52* 1 11 0.90 12 239 0.51*
VLL I 10 209 0.26* 5 213 0.41* 6 239 0.39* 6 108 0.21 27 769 0.34*
VR I 5 98 0.27a 5 92 0.43* 3 58 0.32 2 34 0.16 15 282 0.32*
RDLT -- -- -- 1 20 0.41 1 20 0.25 1 11 0.75 3 51 0.42*
PROCESSING SPEED 16 326 0.35* 8 260 0.57*a 9 327 0.30* 6 111 0.35* 39 1024 0.34*
DSST 12 226 0.62* 6 102 0.68*a 5 96 0.53* 4 68 0.61* 27 492 0.61*a
TMB 12 241 0.19* 7 250 0.34* 7 290 0.23* 6 107 0.21 32 888 0.25*
COGNITIVE FLEXIBILITY & ABSTRACTION 12 227 0.25* 7 237 0.16 4 189 0.10 3 50 0.33 26 703 0.18*
SIM 4 68 1.31* 2 30 0.66* 1 20 0.26 1 11 1.38 8 129 0.72*
WCST 10 185 0.15 7 237 0.14 4 189 0.10 3 50 0.28 24 551 0.14*
VERBAL FLUENCY 15 319 0.44* 7 259 0.28* 5 207 0.06 6 107 0.63* 33 892 0.33*
9 179 0.20 4 66 0.66* 3 65 0.39* 1 11 0.56 17 321 0.34*
BD 8 164 0.26* 3 46 0.65* 2 45 0.58* -- -- -- 13 225 0.38*
CFT 1 22 0.23 2 30 0.52* 1 20 -0.30 1 11 0.52 5 83 0.24
VOT 4 87 0.03 1 20 0.77 1 20 0.25 1 11 0.60 7 138 0.21
MOTOR SKILLS 4 68 0.64* 3 65 0.33 3 66 0.22 2 34 0.20 12 233 0.37*
FTT 4 68 0.64* 3 62 0.27 2 46 0.19 2 34 0.01 11 210 0.32*
GPB/PIN -- -- -- 1 20 0.66 2 39 0.14 2 34 0.39 5 93 0.34*
DELAYED RECALL 13 280 0.25* 4 199 0.46* 5 211 0.46* 3 58 0.30a 25 748 0.37*
LM II 6 108 0.35
a
2 42 0.71* 3 51 0.53* 2 43 0.64* 13 244 0.49*
VLL II 8 173 0.29* 4 199 0.46* 3 186 0.70*a 1 15 -0.46 16 573 0.43*a
VR II 8 165 0.18 3 62 0.63* 2 38 0.80* -- -- -- 13 265 0.38*
a
Table 3: Neuropsychological Change with Second Generation Treatment: Analysis 2.
* Effect Size > 0, p<.05.
Number of Effect Sizes (k), Number of Subjects (N), Mean Effect Size (ES)
Random effects model used to combine ESs, Chi-square p-value<.05.
Risperidone QuetiapineClozapine Olanzapine
VISUOSPATIAL SKILLS
Overall Weighted Effect 
Size
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Abbreviations: VIG=Vigilance, WM=Working Memory, LEARN=Learning, CF & A=Cognitive Flexibility & Abstraction, PS=Processing Speed, VF=Verbal Fluency, VIS=Visuospatial Skills, 
MOTOR=Motor Sk ills, DEL. R.=Delayed Recall. 
Figure 1. Cognitive change with SGAs Compared to Practice Effects. 
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Figure 2. Cognitive change with clozapine, olanzapine, risperidone, and quetiapine: comparison to 
practice effects.
